Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
Solid Q4 and FY performance
Group1
USD million
Q4
Change vs. PY
2022
FY
2022
% USD
% cc
% USD
Change vs. PY
% cc
Net Sales
12,690
-4
3
50,545
-2
4
Core Operating income
4,030
6
15
16,665
0
8
Operating income
1,949
-24
-14
9,197
-21
-13
Net Income
1,466
-91
-90
6,955
-71
-67
Growth ex. prior year Roche income
-12
2
-20
-9
Core EPS (USD)
1.52
9
19
6.12
-3
0
Growth ex. prior year Roche income
12
23
5
14
EPS (USD)
0.69
-91
-89
3.19
-70
-66
Growth ex. prior year Roche income
-8
7
-17
-7
Free Cash Flow
3,552
17
11,945
-10
Growth ex. prior year Roche dividend
17
-6
FINANCIAL PROFILE
1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 50 of the Condensed Financial Report. A table showing the Q4 2022 and FY 2022 key
figures excluding Roche can be found on page 3 and 9 and a reconciliation of 2021 IFRS results and non-IFRS measures core results to exclude the impacts of the 2021 divestment of our Roche investment can be found on page 59 of the
Condensed Interim Financial Report.
37 Investor Relations | Q4 2022 Results
ā NOVARTIS | Reimagining MedicineView entire presentation